# As Sanofi’s Pompe drug shortage drags on, some patients struggle to access treatments

- URL: https://talkfuse.com/story/as-sanofis-pompe-drug-shortage-drags-on-some-patients-struggle-to-access-treatments/
- Published: 2026-11-19T19:38:33+00:00
- Updated: 2026-11-19T23:51:29+00:00
- Original publisher: CNBC (publisher lean: Centre)
- Original article: https://www.cnbc.com/2026/11/19/as-pompe-drug-shortage-drags-on-patients-struggle-to-get-treatments.html
- Topics: Business, Health, Medicine

## Key points

- Sanofi’s Ireland plant issues have disrupted Pompe drug supplies.
- Patients worry that delayed infusions could harm their health.
- The FDA had raised manufacturing concerns months before the shortage.

## Summary

Sanofi’s manufacturing problems in Ireland have disrupted supplies of its Pompe disease treatments, leaving some patients facing delayed or uncertain access. The shortage matters because Pompe is progressive, and patients and advocates say missed infusions can quickly affect health; they have also criticised Sanofi for not giving earlier warning.

The FDA inspected the plant in January 2026 and found violations involving two other drugs. Sanofi began responding in February, but the agency warned in June that it had not addressed an underlying failure to meet manufacturing requirements, and the company says resolving those concerns has contributed to the disruption. One 10-year-old patient has so far kept his fortnightly Lumizyme infusions, while an adult patient’s treatment is on hold; she says previous missed doses left her severely fatigued, short of breath and in pain.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
